<DOC>
	<DOCNO>NCT02682719</DOCNO>
	<brief_summary>The purpose study determine whether LCZ696 ( valsartan/sacubitril ) safe beneficial effect heart blood vessel patient high blood pressure and/or diabetes risk factor develop heart failure ( elevated level natriuretic peptide elevate left atrial volume index ) . Patients randomize receive LCZ696 valsartan ( match placebo ) 18 month assess impact leave ventricular diastolic function .</brief_summary>
	<brief_title>ARNI Asymptomatic Patients With Elevated Natriuretic Peptide Elevated Left Atrial Volume Index eLEvation</brief_title>
	<detailed_description>The STOP-HF prospective , randomized trial demonstrate biomarker driven strategy natriuretic peptide ( NP ) base screen collaborative care general practice help target cardiovascular prevention improve outcome at-risk population patient without heart failure . However , successful , STOP-HF biomarker strategy lack specific pharmacological intervention link screen biomarker , NP . The appropriate therapy build STOP-HF LCZ696 ( sacubitril/valsartan ) , first class angiotensin receptor neprilysin inhibitor ( ARNI ) . As neprilysin degrades biologically active NP , LCZ696 increase myocardial cyclic guanosine monophosphate ( cGMP ) reduce myocardial stiffness hypertrophy . NPs also stimulate natriuresis , diuresis , vasodilation show anti-fibrotic anti-sympathetic benefit could augment STOP-HF preventative strategy . Elevated NP at-risk population independently identify cardiovascular risk , specifically target LCZ696 . In small number patient ( 4 % ) cardiovascular risk factor elevate NP , significant asymptomatic LV systolic dysfunction present RAAS modifying therapy mandate . However , large group patient elevate NP normal systolic function leave ventricle significant isolated diastolic dysfunction . These patient asymptomatic leave ventricular diastolic dysfunction ( ALVDD ) heighten risk heart failure cardiovascular event . The Investigators others , show cardiac inflammation , fibrosis hypertrophy drive pathophysiology . Importantly , currently specific therapy patient , beyond conventional risk factor control . Interrupting pathophysiological process early stage development ventricular dysfunction , may prevent/slow development heart failure also impact development cardiovascular event driven pathophysiological process . This represent novel way modify risk earlier stage natural course cardiovascular disease , target individualized manner . It know suppress RAAS reduce pro-fibrotic impact angiotensin II . Addition neprilysin inhibitor sacubitril LCZ696 , reduce degradation endogenous , cardio-protective , biologically active NPs cGMP augment beneficial impact fibro-inflammation beyond conventional RAAS modifying therapy . There number emerge biochemical imaging surrogate leave ventricular dysfunction , evaluate relatively small population short time frame prospective , phase II study design . Of , one reliable , continuous marker diastolic function heart LAVI . There dramatic impact LCZ696 LAVI comparison valsartan PARAMOUNT study . Furthermore , endpoint precisely define use cardiac magnetic resonance imaging ( cMRI ) phase II design . In study , doppler Echocardiographic image collect correlate cMRI image . Doppler Echocardiography feasible follow study large population . In summary , demonstrated asymptomatic patient elevate NP level high risk heart failure cardiovascular event . Elevated NP set represent protective , endogenous response fibro-inflammation . The predominant cardiac abnormality patient ALVDD , track use LAVI . The hypothesis augment protective fibro-inflammatory response LCZ696 could demonstrate superiority current state art therapy patient hypertension diabetes elevate NP phase II study design , , PARABLE may deliver major clinical innovation prevention cardiovascular disease .</detailed_description>
	<mesh_term>LCZ 696</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>1 . Age &gt; 40yrs 2 . Cardiovascular risk factor ( ) include least one : History hypertension ( medicate great one month ) ; History diabetes ; 3 . Elevated NP : BNP &gt; 50pg/ml NTproBNP &gt; 250 pg/ml 4 . LAVI &gt; 28 mL/m2 obtain Doppler Echocardiography within 6 month prior screen 5 . Subjects must give write informed consent participate study study relate assessment perform 1 . A history heart failure . 2 . A history asymptomatic leave ventricular systolic dysfunction define LVEF read &lt; 50 % , time . 3 . Systolic blood pressure &lt; 100mmHg 4 . Persistent atrial fibrillation . 5 . History hypersensitivity , allergy intolerance LCZ696 , ARB neprilysin therapy excipients contraindication use . 6 . Previous history intolerance recommend target dos ARBs 7 . Subjects require treatment ACE inhibitor ARB 8 . Presence haemodynamically significant mitral /or aortic valve disease . 9 . Presence hemodynamically significant obstructive lesion leave ventricular outflow tract , include aortic stenosis . 10 . Conditions expect compromise survival study period . 11 . Serum potassium level &gt; 5.2 mmol/L screening . 12 . Severe renal insufficiency ( eGFR &lt; 30 mL per minute per 1.73 m2 ) . 13 . Hepatic dysfunction ( Any LFT &gt; 3 time upper limit normal ( ULN ) ) 14 . Concomitant use aliskiren 15 . History angioedema . 16 . History evidence drug alcohol abuse within last 12 month 17 . Malignancy 18 . Women pregnant , breastfeeding , woman child bear potential use estroprogestative oral intrauterine contraception implant , woman use estroprogestative oral intrauterine contraception implant consider stop plan duration study . A postmenopausal state define menses 12 month without alternative medical cause . ( Contraception must continue one week follow discontinuation study drug ) . 19 . Concomitant participation intervention trial 20 . Participation investigational drug trial within one month visit 1 . 21 . Refusal provide informed consent 22 . Subjects contraindication MRI Hypersensitivity gadolinium contain contrast agent Brain aneurysm clip Implanted neural stimulator Implanted cardiac pacemaker defibrillator Cochlear implant Ocular foreign body ( e.g . metal shaving ) Other implanted medical device : ( e.g . SwanGanz catheter ) Insulin pump Metal shrapnel bullet . 23 . Any surgical medical condition might significantly alter absorption , distribution , metabolism , excretion study drug , include limited following : History major gastrointestinal tract surgery include gastrectomy , gastroenterostomy , bowel resection . Inflammatory bowel disease 12 month prior Visit 1 . Any history pancreatic injury , pancreatitis evidence impair pancreatic function/injury indicate abnormal lipase amylase . Evidence hepatic disease determine one following : SGOT SGPT value exceed 3 x ULN Visit 1 , history hepatic encephalopathy , history oesophageal varix , history portocaval shunt .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Natriuretic peptide , brain</keyword>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Cardiovascular prevention</keyword>
	<keyword>Left atrial volume index</keyword>
	<keyword>Angiotensin receptor neprilysin inhibitor</keyword>
	<keyword>LCZ696</keyword>
	<keyword>Valsartan</keyword>
	<keyword>Sacubitril</keyword>
</DOC>